A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy

Clinical Cancer Research

Volumn 13, Issue 23, 2007, Pages 6984-6992

  Zheng, Yingye ^a   Katsaros, Dionyssios ^b   Shan, Shannon J C ^c,d   De La Longrais, Irene Rigault ^b   Porpiglia, Mauro ^b   Scorilas, Andreas ^e   Kim, Nam W ^f   Wolfert, Robert L ^f   Simon, Iris ^f   Li, Lin ^a   Feng, Ziding ^a   Diamandis, Eleftherios P ^c,d,g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c Pediatric Oral and Maxillofacial Surgery   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF ATHENS   (Greece)

^f diaDexus Inc   (United States)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; B7 H4 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; KALLIKREIN; METHOTREXATE; PACLITAXEL; PROTEIN HK10; PROTEIN HK11; PROTEIN HK13; PROTEIN HK14; PROTEIN HK4; PROTEIN HK5; PROTEIN HK6; PROTEIN HK7; PROTEIN HK8; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD80; CA-125 ANTIGEN; CYTOSOL; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; KALLIKREINS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 37249080637     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1409     Document Type: Article

References (56)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol 1999;26:2-7.
3. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
4. Boyce EA, Kohn EC. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets. Int J Gynecol Cancer 2005;15:266-73.
5. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4700-10.
6. Kaern J, Aghmesheh M, Nesland JM, et al. Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors? Int J Gynecol Cancer 2005;15:1014-22.
7. Spentzos D, Levine DA, Kolia S, et al. Unique gene expression profile based on pathologic response in epithelial ovarian cancer. J Clin Oncol 2005;23:7911-18.
8. Bast RC, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15:274-81.
9. Paliouras M, Diamandis EP. The kallikrein world: an update on the human tissue kallikreins. Biol Chem 2006;387:643-52.
10. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-90.
11. Simon I, Zhuo S, Corral L, et al. B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer. Cancer Res 2006;66:1570-75.
12. Pettersson F. Annual report on the treatment in gynecological cancer. Stockholm: International Federation of Gynecology and Obstetrics; 1994. p. 83-102.
13. Day TG, Jr., Gallager HS, Rutledge FN. Epithelial carcinoma of the ovary: prognostic importance of histologic grade. Natl Cancer Inst Monogr 1975;42:15-21.
14. Serov SF, Sorbin LH. Histological typing of ovarian tumors. Geneva (Switzerland):WHO; 1973.
15. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
16. McIntosh MW, Pepe MS. Combining several screening tests: optimality of the risk score. Biometrics 2002;8:657-64.
17. Eguchi S, Copas J. A class of logistic-type discriminant functions. Biometrika 2002;89:1-22.
18. Zheng Y, Cai T, Feng Z. Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics 2006;62:279-287.
19. Duffy MJ. Proteases as prognostic markers in cancer. Clin Cancer Res 1996;2:613-8.
20. Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res 2001;7:2380-6.
21. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res 2001;7:2363-71.
22. Davidson B, Xi Z, Klokk TI, et al. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions. Am J Clin Pathol 2005;123:360-8.
23. Xi Z, Kaern J, Davidson B, et al. Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer. Gynecol Oncol 2004;94:80-5.
24. Kim H, Scorilas A, Katsaros D, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer 2001;84:643-50.
25. Dong Y, Kaushal A, Brattsand M, et al. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res 2003;9:1710-20.
26. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res 2003;63:2223-7.
27. Hibbs K, Skubitz KM, Pambuccian SE, et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 2004;165:397-414.
28. Diamandis EP, Borgono CA, Scorilas A, et al. Immunofluorometric quantification of human kallikrein 5 expression in ovarian cancer cytosols and its association with unfavorable patient prognosis. Tumour Biol 2003;24:299-309.
29. Hoffman BR, Katsaros D, Scorilas A, et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br J Cancer 2002;87:763-71.
30. Tanimoto H, Underwood LJ, Shigemasa K, et al. Increased expression of protease M in ovarian tumors. Tumour Biol 2001;22:11-8.
31. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77.
32. Ni X, Zhang W, Huang KC, et al. Characterisation of human kallikrein 6/protease M expression in ovarian cancer. Br J Cancer 2004;91:725-31.
33. Yousef GM, Borgono CA, White NM, et al. In silico analysis of the human kallikrein gene 6. Tumour Biol 2004;25:282-9.
34. Anisowicz A, Sotiropoulou G, Stenman G, et al. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol Med 1996;2:624-36.
35. Adib TR, Henderson S, Perrett C, et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004;90:686-92.
36. Gilks CB, Vanderhyden BC, Zhu S, et al. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol Oncol 2005;96:684-94.
37. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
38. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004;10:3291-300.
39. Santin AD, Zhan F, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 2004;112:14-25.
40. Shan SJ, Scorilas A, Katsaros D, et al. Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols. Clin Chem 2006;52:1879-86.
41. Tanimoto H, Underwood LJ, Shigemasa K, et al. The stratum corneum chymotryptic enzyme that mediates shedding and desquamation of skin cells is highly overexpressed in ovarian tumor cells. Cancer 1999;86:2074-82.
42. Kyriakopoulou LG, Yousef GM, Scorilas A, et al. Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer. Clin Biochem 2003;36:135-43.
43. Yousef GM, White NM, Michael IP, et al. Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. Tumour Biol 2005;26:227-35.
44. Sidiropoulos M, Pampalakis G, Sotiropoulou G, et al. Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. Tumour Biol 2005;26:324-36.
45. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol 2003;90:44-50.
46. Luo LY, Bunting P, Scorilas A, et al. Human kallikrein 10: a novel tumor marker for ovarian carcinoma? Clin Chim Acta 2001;306:111-8.
47. Luo LY, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 2001;7:2372-9.
48. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 2003;63:807-11.
49. Borgono CA, Fracchioli S, Yousef GM, et al. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer 2003;106:605-10.
50. Chang A, Yousef GM, Scorilas A, et al. Human kallikrein gene 13 (KLK13) expression by quantitative RT-PCR: an independent indicator of favourable prognosis in breast cancer. Br J Cancer 2002;86:1457-64.
51. Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res 2001;7:806-11.
52. Yousef GM, Kyriakopoulou LG, Scorilas A, et al. Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res 2001;6:7811-8.
53. Scorilas A, Borgono CA, Harbeck N, et al. Human kallikrein 13 protein in ovarian cancer cytosols: a new favorable prognostic marker. J Clin Oncol 2004;22:678-85.
54. Tringler B, Liu W, Corral L, et al. B7-H4 overexpression in ovarian tumors. Gynecol Oncol 2006;100:44-52.
55. Shih IeM, Salani R, Fiegl M, et al. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol 2007;105:501-7.
56. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006;2:689-700.